ClinicalTrials.gg
CompletedNCT00129961Updated Apr 11, 2012Results posted

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

A Phase 4 interventional study of sirolimus and cyclosporine or tacrolimus in Skin Neoplasms and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-11.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.

Enrollment
108th of 290
86 · median 44
Started
2005
with 7 others
Phase 4
11 of 381
5 open now
Registered
33rd of 381
by date

Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 108th largest by enrollment of the 290 interventional ones that give a count, is one of 8 that started in 2005, is one of 11 in phase 4, and was the 33rd registered.

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 128 are open to participants now.

Browse Skin Neoplasms studies →

Open to participants now

64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Skin Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.

03

Conditions studied

  • Skin Neoplasms
  • Kidney Transplantation

Browse trials for

Keywords

  • Kidney
  • Transplant
  • Skin Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kidney transplant at least 1 year prior
  • Subjects with a functioning renal allograft with calculated (GFR) ≥40mL/min (Nankivell method) and proteinuria ≤500mg/day.
  • Stable on cyclosporine or tacrolimus-based multi-drug regimen
  • History of NMSC within last 3 years

Exclusion criteria

Exclusion Criteria:

  • History of other cancer within last 3 years
  • NMSC with disease or more than 20 NMSC lesions in last 12 months
  • Multiple organ transplant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    1

    Conversion to a sirolimus-based regimen

    Drug: sirolimus

  • Active comparator
    2

    Continuation of a CNI-based regimen

    Drug: cyclosporine or tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year

    The number of new biopsy-confirmed NMSC lesions per subject per year was calculated by summarizing the total number of new BCC and SCC lesions reported over the observation period and standardizing it to an annual rate by multiplying by 365 and dividing by days on study.

    Time frame: up to 24 months

Secondary outcomes

  1. Time to First Biopsy Confirmed New NMSC Lesion.

    The time to first biopsy confirmed new NMSC lesion starts at 1 day post randomization to biopsy and/or treatment of newly confirmed NMSC lesion.

    Time frame: up to 24 months

  2. Number of Lesion Free Subjects

    The overall number of subjects who were lesion free were compared between treatment groups with the Cochran Mantel Haenszel test stratified by baseline NMSC stratum. Within each stratum, the Fisher exact test was used to compare the proportions of lesion free subjects between treatment groups.

    Time frame: up to 24 months

  3. Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)

    Time frame: up to 24 months

  4. Grade Distribution of NMSC Lesions

    Number of subjects with at least 1 biopsy-confirmed new squamous cell carcinoma (SCC) or basal cell carcinoma (BCC).

    Time frame: up to 24 months

  5. Number of Recurrent NMSC Lesions Per Subject-year

    Recurrent NMSC lesions is defined as recurring at the site of a previously treated lesion.

    Time frame: up to 24 months

  6. Subjects Reporting Incidence of Metastatic Disease Related to NMSC.

    The number of subjects with metastatic disease related to NMSC.

    Time frame: up to 24 months

  7. Death Due to NMSC

    Time frame: up to 24 months

  8. Number of Subjects Who Discontinue Assigned Therapy

    Time frame: up to 24 months

  9. Nankivell-Calculated Glomerular Filtration Rate (GFR)

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using Nankivell. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

    Time frame: At 24 months (week 104)

  10. Serum Creatinine Level

    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatinine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males, however the normal values are age-dependent as elderly patients typically have smaller muscle mass.

    Time frame: At 24 months (Week 104)

  11. Number of Participants That Died

    Time frame: up to 24 months

  12. Graft Survival Measured by Graft Loss

    Graft loss was defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 consecutive weeks), retransplant, or death.

    Time frame: up to 24 months

  13. Number of Subjects With Biopsy-Confirmed Acute Rejection

    Time frame: up to 24 months

  14. Spot Urine Protein:Creatinine Ratio

    Subjects' urine protein:creatinine ratios were summarized by each scheduled visit, and the nonparametric Wilcoxon rank sum test was used to compare the difference between groups.

    Time frame: At 24 months (Week 104)

07

Results

Posted Mar 23, 2012
Limitations and caveats
A blinded review of data in May 2007 determined there was minimal added power in follow-up through 2 years vs. 1 year. The study was then amended to require at least 1 year of follow-up instead of 2 years.

Participant flow

Subjects were recruited in Australia, New Zealand and North America from August 2005 (first subject randomized September 2005) through October 2007.

Participant flow — Overall Study
MilestoneSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Started3947
Completed2024
Not completed1923
Withdrew: Adverse event10
Withdrew: Death11
Withdrew: Withdrawal by sponsor1420
Withdrew: Physician decision10
Withdrew: Withdrawal by subject21
Withdrew: Missing record01

Outcome measures

PrimaryNew Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year

The number of new biopsy-confirmed NMSC lesions per subject per year was calculated by summarizing the total number of new BCC and SCC lesions reported over the observation period and standardizing it to an annual rate by multiplying by 365 and dividing by days on study.

Time frame:
up to 24 months
Reported as:
Number · Standardized Yearly Rate of NMSC
New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year
Standardized Yearly Rate of NMSCSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year1.31 ± 0.522.48 ± 0.69
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Poisson regression · p = 0.022 (Poisson regression was used to model NMSC counts using the years in study as an offset. The generalized estimated equations (GEE) approach was used to estimate parameters and compare treatment differences.)Adjusted by baseline strata; Poisson model = strata + treatment.
SecondaryTime to First Biopsy Confirmed New NMSC Lesion.

The time to first biopsy confirmed new NMSC lesion starts at 1 day post randomization to biopsy and/or treatment of newly confirmed NMSC lesion.

Time frame:
up to 24 months
Reported as:
Median · number of days
Time to First Biopsy Confirmed New NMSC Lesion.
number of daysSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Time to First Biopsy Confirmed New NMSC Lesion.380 ± 42.42163 ± 42.32
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Regression, Cox · p = 0.047Stratified by baseline lesions
SecondaryNumber of Lesion Free Subjects

The overall number of subjects who were lesion free were compared between treatment groups with the Cochran Mantel Haenszel test stratified by baseline NMSC stratum. Within each stratum, the Fisher exact test was used to compare the proportions of lesion free subjects between treatment groups.

Time frame:
up to 24 months
Reported as:
Number · participants
Number of Lesion Free Subjects
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Number of Lesion Free Subjects179
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.015Stratified by baseline lesion strata
SecondaryPercentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)
Time frame:
up to 24 months
Reported as:
Number · Percentage of Participants
Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)
Percentage of ParticipantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
SCC6769
BCC3331
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Chi-squared · p = 0.799
SecondaryGrade Distribution of NMSC Lesions

Number of subjects with at least 1 biopsy-confirmed new squamous cell carcinoma (SCC) or basal cell carcinoma (BCC).

Time frame:
up to 24 months
Reported as:
Number · participants
Grade Distribution of NMSC Lesions
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
SCC Well differentiated517
SCC Moderately differentiated914
SCC Poorly differentiated11
SCC Invasive1024
SCC In Situ1227
SCC Invasive with Perineural Invasion21
SCC Invasive without Perineural Invasion824
BCC Superficial716
BCC Nodular1115
BCC Infiltrative26
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.014Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.491Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.905Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.018Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.012Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.463Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.004Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.094Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.720Stratified by baseline lesion strata
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.227Stratified by baseline lesion strata
SecondaryNumber of Recurrent NMSC Lesions Per Subject-year

Recurrent NMSC lesions is defined as recurring at the site of a previously treated lesion.

Time frame:
up to 24 months
Reported as:
Number · lesions per participant year
Number of Recurrent NMSC Lesions Per Subject-year
lesions per participant yearSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Number of Recurrent NMSC Lesions Per Subject-year0.107 ± 0.090.134 ± 0.10
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Poisson regression · p = 0.748
SecondarySubjects Reporting Incidence of Metastatic Disease Related to NMSC.

The number of subjects with metastatic disease related to NMSC.

Time frame:
up to 24 months
Reported as:
Number · participants
Subjects Reporting Incidence of Metastatic Disease Related to NMSC.
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Subjects Reporting Incidence of Metastatic Disease Related to NMSC.13
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Cochran-Mantel-Haenszel · p = 0.425Stratified by baseline lesion strata
SecondaryDeath Due to NMSC
Time frame:
up to 24 months
Reported as:
Number · participants
Death Due to NMSC
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Death Due to NMSC00
SecondaryNumber of Subjects Who Discontinue Assigned Therapy
Time frame:
up to 24 months
Reported as:
Number · participants
Number of Subjects Who Discontinue Assigned Therapy
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Number of Subjects Who Discontinue Assigned Therapy3123
SecondaryNankivell-Calculated Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using Nankivell. A normal GFR is \> 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR \<15 is consistent with kidney failure.

Time frame:
At 24 months (week 104)
Reported as:
Mean · units on scale
Nankivell-Calculated Glomerular Filtration Rate (GFR)
units on scaleSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Nankivell-Calculated Glomerular Filtration Rate (GFR)72.49 ± 24.4168.42 ± 19.91
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · ANCOVA · p = 0.604
SecondarySerum Creatinine Level

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatinine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males, however the normal values are age-dependent as elderly patients typically have smaller muscle mass.

Time frame:
At 24 months (Week 104)
Reported as:
Mean · μmol/L
Serum Creatinine Level
μmol/LSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Serum Creatinine Level139.35 ± 41.63135.23 ± 37.84
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · ANCOVA · p = 0.672
SecondaryNumber of Participants That Died
Time frame:
up to 24 months
Reported as:
Number · participants
Number of Participants That Died
participantsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Number of Participants That Died11
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Fisher Exact · p = 0.999
SecondaryGraft Survival Measured by Graft Loss

Graft loss was defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 consecutive weeks), retransplant, or death.

Time frame:
up to 24 months
Reported as:
Number · graft loss
Graft Survival Measured by Graft Loss
graft lossSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Graft Survival Measured by Graft Loss21
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Fisher Exact · p = 0.588
SecondaryNumber of Subjects With Biopsy-Confirmed Acute Rejection
Time frame:
up to 24 months
Reported as:
Number · subjects
Number of Subjects With Biopsy-Confirmed Acute Rejection
subjectsSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Number of Subjects With Biopsy-Confirmed Acute Rejection01
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Fisher Exact · p = 0.999
SecondarySpot Urine Protein:Creatinine Ratio

Subjects' urine protein:creatinine ratios were summarized by each scheduled visit, and the nonparametric Wilcoxon rank sum test was used to compare the difference between groups.

Time frame:
At 24 months (Week 104)
Reported as:
Median · ratio (mg/mg)
Spot Urine Protein:Creatinine Ratio
ratio (mg/mg)Sirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
Spot Urine Protein:Creatinine Ratio0.14 ± 0.280.12 ± 0.08
Statistical analysis
  • Sirolimus (SRL) Based Regimen vs Calcineurin Inhibitor (CNI) Based Regimen · Wilcoxon (Mann-Whitney) · p = 0.030

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sirolimus (SRL) Based Regimen—15/39 (38.5%)38/39 (97.4%)
Calcineurin Inhibitor (CNI) Based Regimen—21/47 (44.7%)40/47 (85.1%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
PneumoniaRespiratory, thoracic and mediastinal disorders3/392/47
PneumonitisRespiratory, thoracic and mediastinal disorders3/390/47
SepsisGeneral disorders0/393/47
GastroenteritisGastrointestinal disorders1/393/47
Prostatic carcinomaRenal and urinary disorders2/391/47
Rectal hemorrhageGastrointestinal disorders0/392/47
Skin carcinomaSkin and subcutaneous tissue disorders1/392/47
Skin melanomaSkin and subcutaneous tissue disorders0/392/47
Urinary tract infectionRenal and urinary disorders1/392/47
Allergic reactionGeneral disorders1/390/47
Most frequent other events
Showing 10 of 178
Most frequent other events
EventSirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based Regimen
DiarrheaGastrointestinal disorders16/396/47
Peripheral edemaMetabolism and nutrition disorders16/393/47
Mouth ulcerationGastrointestinal disorders13/390/47
RashSkin and subcutaneous tissue disorders13/391/47
Cough increasedRespiratory, thoracic and mediastinal disorders8/396/47
AcneSkin and subcutaneous tissue disorders7/391/47
AlbuminuriaRenal and urinary disorders7/390/47
PainGeneral disorders6/395/47
HypertensionCardiac disorders6/394/47
PneumonitisRespiratory, thoracic and mediastinal disorders6/390/47

Baseline characteristics

Age Continuous
Age Continuous(years)Sirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based RegimenTotal
Mean59.08 (36 to 76)58.98 (37 to 78)59.02 (36 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Sirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based RegimenTotal
Female81321
Male313465
Stratification Group
Stratification Group(subjects)Sirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based RegimenTotal
0-5 Lesions in 12 months prior333972
6-20 Lesions in 12 months prior6814
Time from Current Transplantation to Randomization
Time from Current Transplantation to Randomization(Months)Sirolimus (SRL) Based RegimenCalcineurin Inhibitor (CNI) Based RegimenTotal
Mean114.98 ± 57.63109.57 ± 55.08112.02 ± 55.98
08

Study locations

23 sites
  • San Diego, California 92103, United States
  • San Francisco, California 94143, United States
  • Gainesville, Florida 32610, United States
  • Atlanta, Georgia 30309, United States
  • Chicago, Illinois 60612, United States
  • Durham, North Carolina 27710, United States
  • Cincinnati, Ohio 45267, United States
  • Portland, Oregon 97239, United States
  • Philadelphia, Pennsylvania 19102, United States
  • Charleston, South Carolina 29425, United States
  • Nashville, Tennessee 37232, United States
  • Madison, Wisconsin 53792, United States
  • Camperdown, New South Wales 2050, Australia
  • Wooloongabba, Queensland 4102, Australia
  • Woodville, South Australia 5011, Australia
  • Adelaide, SA 5000, Australia
  • Clayton, VIC 3169, Australia
  • Herston, QLD 4029, Australia
  • Parkville, VIC 3050, Australia
  • Randwick, NSW 2031, Australia
  • Westmead, NSW 2145, Australia
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Grafton, Auckland 1031, New Zealand
09

References and documents

Publications

  • Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012 May;12(5):1146-56. doi: 10.1111/j.1600-6143.2012.04004.x. Epub 2012 Mar 15. PubMed 22420843 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2005
First posted
Aug 12, 2005
Start
Aug 2005
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Mar 23, 2012
Last update
Apr 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00129961
Responsible party
Sponsor
First posted
Aug 12, 2005
Start date
Aug 2005
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Mar 23, 2012
Last update
Apr 11, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Canada, clintrialparticipation@wyeth.com
Trial Manager
principal investigator · For Australia, medinfo@wyeth.com
Trial Manager
principal investigator · For New Zealand, medinfo@wyeth.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion